Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM – Free Report) – Stock analysts at HC Wainwright raised their Q3 2023 earnings estimates for shares of Actinium Pharmaceuticals in a research note issued to investors on Tuesday, August 15th. HC Wainwright analyst J. Pantginis now expects that the biotechnology company will earn ($0.39) per share for the quarter, up […]
Investment Analysts’ price target changes for Tuesday, August 15th: Arcellx (NASDAQ:ACLX) had its price target increased by HC Wainwright from $49.00 to $50.00. The firm currently has a buy rating on the stock. Arcellx (NASDAQ:ACLX) had its target price increased by Robert W. Baird from $40.00 to $52.00. They currently have an outperform rating on […]
/PRNewswire/ Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today.
Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM – Free Report) was the recipient of a significant growth in short interest during the month of June. As of June 15th, there was short interest totalling 1,680,000 shares, a growth of 37.7% from the May 31st total of 1,220,000 shares. Based on an average trading volume of 256,200 shares, the […]